Sign In
Buy NVO
$47.42
+1.52 (+3.31%)
At Close: Jun 23, 2026
Novo Nordisk Surges as Hims & Hers Withdraws Weight-Loss Pill
07:39am, Monday, 09'th Feb 2026
Shares of Novo Nordisk (NVO, Financials) rose 8% after Hims and Hers Health decided not to sell a compounded form of semaglutide, the primary ingredient in the we
Novo Nordisk A/S - share repurchase programme
07:16am, Monday, 09'th Feb 2026
Bagsværd, Denmark, 9 February 2026 – On 4 February 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Co
Novo Nordisk sues Hims & Hers over patent infringement
07:08am, Monday, 09'th Feb 2026
Novo Nordisk said on Monday it has filed a lawsuit against U.S. telehealth company Hims & Hers for infringing on the Danish group's patents.
Novo Nordisk sues Hims & Hers over cheaper copycat versions of Wegovy pill, injections
07:00am, Monday, 09'th Feb 2026
Novo Nordisk is asking the court to permanently ban Hims from selling compounded versions of its drugs that infringe on the company's patents, and is seeking to recover damages. The move escalates the
Here's why Ozempic stock is soaring today
06:57am, Monday, 09'th Feb 2026
With its moat of widely popular direct and roundabout weight-loss drugs Ozempic and Wegovy preserved, the Danish medical giant Novo Nordisk (NYSE: NVO) saw its stock price fly early on Monday, Februar
Hims & Hers Falls 14% After It Pulls Pulls Copycat Wegovy Pill—Novo Nordisk Up 8%
05:40am, Monday, 09'th Feb 2026
Faced with legal action, Hims and Hers walked back on its plans to launch the cheaper drug in an announcement Saturday. The company said: “Since launching the compounded semaglutide pill on our plat
Hims & Hers Stock Plunges 15%. Why Losing the Novo Wegovy Battle Is a Blow.
05:11am, Monday, 09'th Feb 2026
Heightened regulatory scrutiny could be a major blow for the online drug retailer, which just shelved its plan for a Wegovy copycat.
Novo Nordisk Shares Jump After Hims & Hers Scraps Plan For Copycat Weight-Loss Pill
04:40am, Monday, 09'th Feb 2026
The telehealth provider said it would no longer offer access to a compounded version of Wegovy after Novo Nordisk had threatened legal action.
Novo Nordisk surges as Hims & Hers pulls copycat pill
04:13am, Monday, 09'th Feb 2026
Hims & Hers has said it will stop selling its discounted version of Novo Nordisk's weight-loss pill Wegovy, boosting the stock in European trade.
Novo Nordisk pops 8% after Hims & Hers pulls copycat weight-loss pill
03:12am, Monday, 09'th Feb 2026
Novo Nordisk, maker of Wegovy, saw its stock rise 8% after the opening bell on Monday. The company and the U.S. Food and Drug Administration threatened legal action against Hims & Hers, over its plan
Novo Nordisk shares rise as Hims abandons $49 weight-loss pill
02:45am, Monday, 09'th Feb 2026
Novo Nordisk's Frankfurt-listed shares rose 4.5% on Monday after telehealth firm Hims & Hers reversed its launch of a $49 compounded weight-loss pill over the weekend, following legal threats from Nov
Novo Nordisk Plunges Nearly 15% After Earnings. Here's What Investors Need to Know.
04:05pm, Sunday, 08'th Feb 2026
Novo Nordisk is expecting earnings to decline in 2026. The company's GLP-1 pill has seen more demand than management expected.
LLY Gains on NVO Losses & Outlook for Weight Loss Drug Trade
01:00pm, Sunday, 08'th Feb 2026
Novo Nordisk (NVO) is down 40% year-over-year while Eli Lilly (LLY) is up 30%. It's a shake-up in the GLP-1 trade that few expected, especially with Matt Maley pointing out that Novo Nordisk originall
Medicare Changes in 2026 Every Retiree Needs to Know: The Good, the Bad, and the Ugly
04:44am, Sunday, 08'th Feb 2026
Retirees should brace themselves for both positive and negative changes to Medicare this year.
Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon.
09:30pm, Saturday, 07'th Feb 2026
Eli Lilly's stock price rose sharply as demand for its GLP-1 drugs increased. Novo Nordisk is the second fiddle in GLP-1 drugs, but its GLP-1 pill is seeing strong demand.
